Skip to main content
SpringerLink
Log in

Clinical utility of tumor markers in hepatocellular and pancreatic carcinomas

  • Basic Knowledge of Interest
  • Published:
Journal of Hepato-Biliary-Pancreatic Surgery

Abstract

Because they show high levels in hepatocellular carcinoma, α-fetoprotein and des-γ-carboxyprothrombin are clinically useful tumor markers for differentiating hepatocellular carcinoma from other hepatic diseases. The two are useful complementary markers of hepatocellular carcinoma because they do not correlate with each other. A typical marker of pancreatic cancer is carbohydrate antigen (CA)19-9. Over a period of more than 10 years, many markers resembling CA19-9 have been identified, but none are markedly superior to CA19-9, and the sensitivity of these markers in pancreatic cancer is only 65%–80%. Tumor markers are not useful for the early diagnosis of either hepatocellular carcinoma or pancreatic cancer. They are, however, considered to be useful for monitoring after treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kondo H, Sugano K, Fukayama N, Kyogoku A, Nose H, Shimada K, Ohkura H, Ohtsu A, Yoshida S, Shimosato Y (1994) Detection of point mutations in the K-ras oncogene at codon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 73:1589–1594

    CAS  PubMed  Google Scholar 

  2. Watanabe H, Sawabu N, Ohta H, Satomura Y, Yamakawa O, Motoo Y, Okai T, Takahashi H, Wakabayashi T (1993) Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res 84:961–965

    CAS  PubMed  Google Scholar 

  3. Jones HB (1948) On a new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Lond [Biol] 138:55–62

    Google Scholar 

  4. Fishman WH (1983) Oncodevelopmental markers. In: Fishman WH (ed) Oncodevelopmental markers. Academic, New York, pp. 4–16

    Google Scholar 

  5. Abelev GI, Perova SD, Khramkova NI (1963) Production of embryonal α-globulin by transplantable mouse hepatoma. Transplantation 1:174–180

    CAS  PubMed  Google Scholar 

  6. Koprowski HZ, Steplewski K, Mitchell M, Herlyn D, Herlyn P (1979) Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell. Genet 5:957–971

    Article  CAS  PubMed  Google Scholar 

  7. Jackson CM (1987) Mechanisms of prothrombin activation. In: Colman RW, Hirsh J, Marder VI, Salzman ED (eds) Hemostasis and thrombosis. JB Lippincott, Philadelphia, pp 135–147

    Google Scholar 

  8. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo K-J, Lee S-D (1984) Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310:1427–1431

    CAS  PubMed  Google Scholar 

  9. Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T (1991) Clinical usefulness of des-γ-carboxy prothrombin assay in early diagnosis of hepatocellular carcinoma. Dig Dis Sci 36:1787–1792

    Article  CAS  PubMed  Google Scholar 

  10. Okuda K, Peters RL, Simson IW (1984) Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas: Proposal of new classification. Cancer 54: 2165–2173

    CAS  PubMed  Google Scholar 

  11. Nakao A, Virji A, Carr B, Iwatsuki S, Starzl E (1991) Abnormal prothrombin (des-γ-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology 38:450–453

    CAS  PubMed  Google Scholar 

  12. Takami H (1992) PIVKA-II (in Japanese). Shokakigeka (Gastroenterological Surg) 15:1154–1156

    Google Scholar 

  13. Oguro H, Ooyagi Y, Saito A, Yokota T, Mori S, Suda T, Igasashi K, Ichida T, Uemura A, Asakura H (1991) Usefulness of simultaneous measurement of AFP and PIVKA-II in the judgement of efficacy of treatment for hepatocellular carcinoma (in Japanese). Kanzo (Liver) 81:1063

    Google Scholar 

  14. Safi F, Beger HG, Bittner R, Buchler M, Krautzberger W (1986) CA19-9 and pancreatic adenocarcinoma. Cancer 57:779–783

    CAS  PubMed  Google Scholar 

  15. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Makela O, Jalanko H (1986) Evaluation of CA19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer 53:197–202

    CAS  PubMed  Google Scholar 

  16. Rothlin MA, Joller H, Largiader F (1933) CA242 is a new tumor marker for pancreatic cancer. Cancer 71:701–707

    Google Scholar 

  17. Friess H, Buchler M, Auerbach B, Weber A, Malfertheiner P, Hammer K, Madry N, Greiner S, Bosslet K, Beger G (1993) CA494-A new tumor marker for the diagnosis of pancreatic cancer. Int J Cancer 53:759–763

    CAS  PubMed  Google Scholar 

  18. Sperti C, Pasquali C, Catalini S, Cappellazzo F, Bonadimani B, Behboo R, Pedrazzoli S (1993) CA19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol 52:137–141

    CAS  PubMed  Google Scholar 

  19. Saito S, Taguchi K, Nishimura N, Watanabe A, Ogoshi K, Niwa M, Furukawa T, Takahashi M (1993) Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma. Cancer 72:381–388

    CAS  PubMed  Google Scholar 

  20. Sharma MP, Gregg JA, Loewenstein MS, McCabe RP, Zamcheck N (1976) Carcmoembryonic antigen activity in pancreatic juice of patients with pancreatic carcinoma and pancreatitis. Cancer 38:2457–2461

    CAS  PubMed  Google Scholar 

  21. Wakabayashi T, Sawabu N, Takemori Y, Satomura Y, Kidani H, Ohta H (1993) Diagnostic significance of cancer-associated carbohydrate antigen (CA19-9) concentration in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis. Pancreas 8:151–159

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Surgery, Teikyo University School of Medicine, 2-11-1, Kaga. Itabashi-ku, 173, Tokyo, Japan

    Hiroshi Takami & Tadahiro Takada

Authors
  1. Hiroshi Takami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tadahiro Takada
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Takami, H., Takada, T. Clinical utility of tumor markers in hepatocellular and pancreatic carcinomas. J Hep Bil Pancr Surg 2, 395–400 (1995). https://doi.org/10.1007/BF02349256

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02349256

Key words

Search

Navigation